The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Abstract

Objective: Sarcoidosis is a chronic systemic inflammatory disease which can affect multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue mediated inflammation in the pathogenesis of the inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim is to assess serum visfatin levels in sarcoidosis and its relation with other markers of inflammation (CRP, ACE and ESR). Material and Methods: We enrolled 59 patients with sarcoidosis and 21 healthy controls. We measured plasma levels of visfatin along with serum CRP, ESR, ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China). Results: Visfatin levels were not significantly different between patients and control subjects (29.9±15.8 ng/ml for patients and 23.93±16.73 ng/ml for controls, p=0.15) and there was no correlation between visfatin and serum CRP, ACE or ESR in patients with sarcoidosis. Conclusion: Visfatin recently is being discussed as biomarker for inflammatory diseases in several studies and results are controversial. In our study, no differences were found in serum level of visfatin between patients with sarcoidosis and control group.

Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2

“…With the exception of IL-8, each biomarker in the sarcoidosis panel (eNAMPT, IL-6, ANG-2 IL-1RA, and HBEGF) accurately discriminated between healthy controls and sarcoidosis subjects, with an optimal threshold > 74%. Our plasma eNAMPT results strongly contrast with a previous report indicating no difference between sarcoidosis and healthy controls (38), possibly reflecting differences in studied cohorts as well as biomarker analytic methodologies (commercial ELISA vs. MSD). Each panel biomarker exhibited unique biomarker properties with IL-1RA and ANG-2 exhibiting the most diagnostic accuracy in distinguishing sarcoidosis from healthy subjects.…”

Darier-Roussy Subcutaneous Sarcoidosis Masquerading as Multiple Abscesses: A Report of a Rare Case

“…Acute phase reactants, such as ESR and CRP, have been used regularly in clinical practice in the workup of skin infections and even showed good results in predicting the severity of such conditions [14]. Also, ESR and CRP were found to be elevated in sarcoidosis patients [15]; similarly, this was noted in our patient. In the literature, case studies reported an overlap between subcutaneous sarcoidosis and skin infections.…”